Private Market View

GenPharmaChain

London, United Kingdom · Founded 2025 · Privately Held (backing)

Last price · $/share
Implied valuation
Total raised
$500K
Last round

Key facts

  • It has raised $500K; the latest was Seed Round ($500K) in Mar 2025.
  • Notable investors include Alphabet, Amazon Web Services, Avatia Pharmaceutical, FNODE Venture, M2M Capital (HK)6 tracked in total.
  • Status: Privately Held (backing).
Free account
See the evidence behind this price
  • ·The complete investor list — 6 names
  • ·Watchlist + deal alerts for GenPharmaChain
  • ·The full record, as it builds
Create free account
No card required

Funding rounds

No rounds on record

No funding rounds for GenPharmaChain are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About GenPharmaChain

Developer of blockchain and decentralized technology designed to refine artificial intelligence-driven pharmaceutical models. The company's technology offers a production and distribution model of generic drugs, ensuring transparency, traceability, lower costs, and greater accessibility, enabling scientists to integrate modules to simulate drug interactions, facilitating biomedical research.

Sector
Healthcare
HQ
London, United Kingdom
Founded
2025
Ownership
Privately Held (backing)
PA Mark — not yet priced

GenPharmaChain doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in GenPharmaChain shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on GenPharmaChain in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.